Immunomedics Cancer Drugs Clinical Pipeline Insight

Number of pages

For Wire/Bank transfer, contact us at

Electronic Access - Single User License
CD-ROM Mail Delivery
Hard Copy Mail Delivery
Electronic Access - Multi-User License

“Immunomedics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Immunomedics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in preclinical phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Immunomedics - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Immunomedics

  1.1 Business Overview

  1.2 Immunomedics Cancer Pipeline Overview


2. Immunomedics Cancer Drugs in Preclinical Phase

  2.1 Antibody Diagnostics and Therapeutics – Immunomedics

  2.2 Antibody Therapeutics – Immunomedics

  2.3 SN 38 Immunoconjugates – Immunomedics

  2.4 Dendritic Cell Vaccines – Immunomedics


3. Immunomedics Cancer Drugs in Phase-I

  3.1 IMMU 114

  3.2 Labetuzumab Anti-DTPA-Indium Bispecific Monoclonal Antibody


4. Immunomedics Cancer Drugs in Phase-I/II

  4.1 TF 2-Targeted Cancer Therapy

  4.2 Epratuzumab Y-90


5. Immunomedics Cancer Drugs in Phase-II

  5.1 Sacituzumab Govitecan

  5.2 Labetuzumab Govitecan

  5.3 Veltuzumab


6. Immunomedics Cancer Drugs in Phase-III

  6.1 Epratuzumab

  6.2 Y-90 Clivatuzumab Tetraxetan


7. No Development Reported in Cancer Drug in Clinical Pipeline

  7.1 Labetuzumab

  7.2 Pentacea

  7.3 Milatuzumab-Doxorubicin Conjugate

  7.4 T Cell Gene Therapy – Immunomedics

  7.5 Labetuzumab Y-90

  7.6 Peginterferon alpha 2b Molecules – Immunomedics

  7.7 RS7-Based Monoclonal Antibodies – Immunomedics

  7.8 CD74-Targeted Cancer Therapeutics – Immunomedics

  7.9 MyelomaCide

  7.10 Boronated Bispecific Antibodies – Immunomedics

  7.11 Labetuzumab-PE40 Conjugate

  7.12 Cancer and Infectious Diseases Vaccines - Immunomedics/Alexis Biotech

  7.13 Epratuzumab-Thorium-227 Conjugate - Algeta/ Immunomedics


8. Market Withdrawal in Cancer Drug in Clinical Pipeline

  8.1 Tc 99m Arcitumomab


9. Discontinued in Cancer Drug in Clinical Pipeline

  9.1 Milatuzumab

  9.2 Bectumomab

  9.3 AFP-Scan

  9.4 Epratuzumab I-131

  9.5 Monoclonal Antibody AFP-I-131

  9.6 ImmuRAIT-Re-188

  9.7 Tacatuzumab-Y-90

  9.8 Bispecific Anticancer Antibodies - Schering/IBC Pharmaceuticals

  9.9 RNAse Monoclonal Antibody-LL2-I-131-Conjugate

  9.10 Doxorubicin-Anti-CEA Monoclonal Antibody Conjugate


10. Suspended in Cancer Drug in Clinical Pipeline

  10.1 Labetuzumab I-131

Figure 1-1: Immunomedics Cancer Pipeline by Phase (%)

Figure 1-2: Immunomedics Cancer Pipeline by Phase (Number)

Figure 1-3: Immunomedics Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Immunomedics Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)